A “request” that manufacturers of testosterone replacement therapy (TRT) products update their prescribing information to reflect new clinical evidence on cardiovascular safety, prostate cancer risk, and use in age‑related hypogonadism has been made by the US Food and Drug Administration (FDA).
The agency’s action follows a multi‑year review of